Literature DB >> 8807057

Antipneumococcal activities of RP 59500 (quinupristin-dalfopristin), penicillin G, erythromycin, and sparfloxacin determined by MIC and rapid time-kill methodologies.

G A Pankuch1, C Lichtenberger, M R Jacobs, P C Appelbaum.   

Abstract

Previous time-kill studies have shown that RP 59500 is rapidly bactericidal against pneumococci. To extend these findings, the activities of RP 59500, its two components RP 57669 RP 54476, penicillin G, erythromycin and sparfloxacin against 26 penicillin-susceptible, 25 penicillin-intermediate, and 25 penicillin-intermediate, and 25 penicillin-resistant pneumococci were determined by the agar dilution MIC and the time-kill testing methodologies within 10 min (ca. 0.2 h) and at 1 and 2 h. Respective agar dilution MICs at which 90% of isolates are inhibited for penicillin-susceptible, -intermediate, and -resistant strains were as follows: penicillin G, 0.03, 1, and 4 micrograms/ml;RP 59500, 1, 1, and 1 microgram/ml; RP 57669, 8, 32, and 16 micrograms/ml; RP 54476, > 128, > 128, and > 128 micrograms/ml; erythromycin, 0.06, 2, and > 128 micrograms/ml; and sparfloxacin, 1, 0.5, and 0.5 microgram/ml. RP 59500 was equally active (MIC at which 90% of isolates are inhibited, 1.0 microgram/ml) against erythromycin-susceptible and -resistant strains. Time-kill testing results showed that only RP 59500 at one to four times the MIC killed pneumococci at 0.2 h; RP 59500 was also the most active compound at 1 and 2 h. By comparison, penicillin and sparfloxacin at one, two, and four times the MICs reduced the original inoculum by > or = 1 log at 2 h for 46, 80, and 95% and for 50, 72, and 86% of strains, respectively. The killing activity of RP 59500 was the same against erythromycin-susceptible and -resistant strains. RP 57669, RP 54479, and erythromycin were either inactive or bacteriostatic at 2 h. Of all drugs tested, RP 59500 yielded the most rapid killing.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8807057      PMCID: PMC163390     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

Review 1.  Treatment and diagnosis of infections caused by drug-resistant Streptococcus pneumoniae.

Authors:  M R Jacobs
Journal:  Clin Infect Dis       Date:  1992-07       Impact factor: 9.079

2.  Importance of bacterial growth phase in determining minimal bactericidal concentrations of penicillin and methicillin.

Authors:  K S Kim; B F Anthony
Journal:  Antimicrob Agents Chemother       Date:  1981-06       Impact factor: 5.191

Review 3.  Antimicrobial resistance in Streptococcus pneumoniae: an overview.

Authors:  P C Appelbaum
Journal:  Clin Infect Dis       Date:  1992-07       Impact factor: 9.079

4.  Emergence of drug-resistant pneumococcal infections in the United States.

Authors:  R F Breiman; J C Butler; F C Tenover; J A Elliott; R R Facklam
Journal:  JAMA       Date:  1994-06-15       Impact factor: 56.272

5.  Activity of oral antibiotics in middle ear and sinus infections caused by penicillin-resistant Streptococcus pneumoniae: implications for treatment.

Authors:  C T Nelson; E O Mason; S L Kaplan
Journal:  Pediatr Infect Dis J       Date:  1994-07       Impact factor: 2.129

6.  Susceptibilities of penicillin-susceptible and -resistant strains of Streptococcus pneumoniae to RP 59500, vancomycin, erythromycin, PD 131628, sparfloxacin, temafloxacin, win 57273, ofloxacin, and ciprofloxacin.

Authors:  S K Spangler; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

Review 7.  Management of infections caused by antibiotic-resistant Streptococcus pneumoniae.

Authors:  I R Friedland; G H McCracken
Journal:  N Engl J Med       Date:  1994-08-11       Impact factor: 91.245

8.  Antimicrobial activity against Staphylococcus aureus of semisynthetic injectable streptogramins: RP 59500 and related compounds.

Authors:  J C Barrière; D H Bouanchaud; J M Paris; O Rolin; N V Harris; C Smith
Journal:  J Antimicrob Chemother       Date:  1992-07       Impact factor: 5.790

9.  In vitro activities of 12 orally administered antimicrobial agents against four species of bacterial respiratory pathogens from U.S. Medical Centers in 1992 and 1993.

Authors:  A L Barry; M A Pfaller; P C Fuchs; R R Packer
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

10.  Increased rate of isolation of penicillin-resistant Streptococcus pneumoniae in a children's hospital and in vitro susceptibilities to antibiotics of potential therapeutic use.

Authors:  E O Mason; S L Kaplan; L B Lamberth; J Tillman
Journal:  Antimicrob Agents Chemother       Date:  1992-08       Impact factor: 5.191

View more
  19 in total

1.  Antipneumococcal activities of GAR-936 (a new glycylcycline) compared to those of nine other agents against penicillin-susceptible and -resistant pneumococci.

Authors:  D B Hoellman; G A Pankuch; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

2.  Antipneumococcal activity of ertapenem (MK-0826) compared to those of other agents.

Authors:  Glenn A Pankuch; Todd A Davies; Michael R Jacobs; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

3.  Antipneumococcal activity of BMS 284756 compared to those of six other agents.

Authors:  Glenn A Pankuch; Kensuke Nagai; Todd A Davies; Michael R Jacobs; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

Review 4.  Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections.

Authors:  H M Lamb; D P Figgitt; D Faulds
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

5.  Resistance to macrolides and related antibiotics in Streptococcus pneumoniae.

Authors:  Roland Leclercq; Patrice Courvalin
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191

6.  Antipneumococcal activities of gemifloxacin compared to those of nine other agents.

Authors:  T A Davies; L M Kelly; G A Pankuch; K L Credito; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

7.  In vitro selection of resistance to clinafloxacin, ciprofloxacin, and trovafloxacin in Streptococcus pneumoniae.

Authors:  K Nagai; T A Davies; G A Pankuch; B E Dewasse; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

8.  Postantibiotic effect and postantibiotic sub-MIC effect of quinupristin-dalfopristin against gram-positive and -negative organisms.

Authors:  G A Pankuch; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

9.  Activity of HMR 3647 compared to those of five agents against Haemophilus influenzae and moraxella catarrhalis by MIC determination and time-kill assay.

Authors:  G A Pankuch; D B Hoellman; G Lin; S Bajaksouzian; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

Review 10.  Streptogramins and their potential role in geriatric medicine.

Authors:  B M Lomaestro; L L Briceland
Journal:  Drugs Aging       Date:  1998-12       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.